Delivery Order SPE2DB20D1110-SPE2DB25FK44J
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets in a 90-count quantity. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $28,009.13 and is scheduled for completion by September 10, 2025. The contract represents a single line item fulfillment under AmerisourceBergen's existing pharmaceutical supply vehicle with DLA, with performance to occur...
- The Defense Logistics Agency awarded a delivery order valued at $2,934.36 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) on September 16, 2025. This firm fixed price delivery order, with a completion date of September 17, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. The pharmaceutical product...
- The Defense Logistics Agency awarded a delivery order valued at $2,491.29 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's corporate headquarters location. The delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity, with a contract ceiling value of $7,054.75. This is a firm fixed price, non-set-aside delivery order with a completion date of September 11, 2025, and performance location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,456.18 delivery order on August 14, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count). This competitive award utilized firm fixed price contracting with no set-aside designation and an ultimate completion date of August 15, 2025. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $5,910.20 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in quantities of 90 units. This firm fixed-price delivery order, which is not set-aside designated, is set to complete on July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $7,415.63 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-25 mg tablets (1,000 units) on September 16, 2025, with an ultimate completion date of September 17, 2025. This non-set-aside contract was awarded under firm fixed-price terms and represents a single delivery order fulfilling pharmaceutical supply requirements for federal medical procurement. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $22,817.18 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-25 mg tablets (90-count) under a firm fixed-price contract. The award was made on August 29, 2025, with an ultimate completion date of September 2, 2025, and the product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) valued at $9,377.10. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive procurement for pharmaceutical supplies supporting military and federal healthcare systems. The contract requires completion by September 18, 2025, with performance at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $24,691.64 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 100-25 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's existing Indefinite Delivery Contract...
- SPE2DB20D1110Indefinite Delivery Contract
- SPE2DB20D1110-SPE2DB25FK44JDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,696.51 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets in a 90-count quantity. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 24, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal healthcare systems. This delivery order represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 through December 2026. As a prime vendor under this comprehensive pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of medications and medical commodities to support military healthcare programs globally, including specialty medications, generic drugs, vaccines, and related medical supplies across multiple therapeutic domains. The company's federal contract portfolio demonstrates consistent capability in fulfilling competitive procurements for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.7k | 9/23/25 |